Peripheral Vascular Disease
Conditions
Keywords
Peripheral Vascular Disease, Peripheral Artery Disease, Radiofrequency
Brief summary
The objective of this clinical investigation is to evaluate the safety and efficacy of the Minnow Medical GRST™ Peripheral Catheter System in the treatment of de novo lesions in the superficial femoral artery (SFA) or the popliteal artery.
Interventions
Treatment to dilate stenoses and reduce plaque in treated vessels
Sponsors
Vessix Vascular, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is ≥18 of age. 2. Patient is Rutherford category 2-4. 3. De novo single lesion with a diameter stenosis (%DS) of ≥50% 4. Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of \<99%. 5. Target lesion stenosis has a length of ≤100 mm based on visual assessment. 6. Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment. 7. Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot. 8. Patient is willing and able to provide written informed consent prior to any study specific procedure. 9. Patient is willing and able to comply with specified follow-up evaluations at the specified times.
Exclusion criteria
1. Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area. 2. Evidence of thrombus in the target vessel. 3. Prior ipsilateral or contralateral lower limb arterial bypass. 4. Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure. 5. Target lesion is severely calcified. 6. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated). 7. Any planned surgery within 30 days of the study procedure. 8. Renal failure (serum creatinine \> 2.0 mg/dL). 9. Female with childbearing potential without a negative pregnancy test. 10. Patient has had an organ transplant. 11. Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study. 12. In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Clinical Events Rate | Up to 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Binary Restenosis | 30 days, 3 months, 6 months and 12 months |
| Target Lesion Revascularization | 30 days, 3 months, 6 months and 12 months |
| Amputation Rate | 30 days, 3 months, 6 months, and 12 months |
| Technical Success | Treatment |
| Serious Adverse Events rate, including Major Adverse Clinical Events | 30 days, 3 months, 6 months, and 12 months |
Countries
Germany
Outcome results
None listed